AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24917198 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnenolone (titrated to 500 mg/day)
Number of subjects: 80
Study 24917198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 22532639 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous NSAID treatment
Number of subjects: 150
Study 22532639 — intervention group
Group type: COMPARATOR
Intervention: On-demand NSAID treatment
Number of subjects: 150
Study 22532639 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (continuous and on-demand)
Number of subjects: 150
Study 20360277 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric advance directives (PADs) documenting medication preferences
Number of subjects: 123
Study 20360277 — intervention group
Group type: EXPERIMENTAL
Intervention: Being prescribed at least one medication requested in the psychiatric advance directive
Number of subjects: 123
Study 18585837 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) therapy
Number of subjects: 39
Study 18585837 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin-inhibitor (CNI) therapy (Control)
Number of subjects: 39
Study 15812073 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐tocopherol (400 IU/day)
Number of subjects: 540
Study 15812073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 540
Study 12934178 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir/ritonavir (Idv/Rtv; 800/100 mg 2 times daily)
Number of subjects: 306
Study 12934178 — intervention group
Group type: COMPARATOR
Intervention: Saquinavir/ritonavir (Sqv/Rtv; 1000/100 mg 2 times daily)
Number of subjects: 306
Study 12934178 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir/ritonavir (Idv/Rtv)
Number of subjects: 306
Study 12934178 — intervention group
Group type: COMPARATOR
Intervention: Saquinavir/ritonavir (Sqv/Rtv)
Number of subjects: 306
Study 10800876 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg salbutamol and 500 microg ipratropium
Number of subjects: 50
Study 10800876 — intervention group
Group type: COMPARATOR
Intervention: 5 mg salbutamol
Number of subjects: 50
Study 10800876 — intervention group
Group type: COMPARATOR
Intervention: 500 microg ipratropium
Number of subjects: 50
Study 8862477 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet at 1.5 x RMR with an additional 0.6 x RMR as protein
Number of subjects: 6
Study 8862477 — intervention group
Group type: EXPERIMENTAL
Intervention: High Carbohydrate (HC) diet at 1.5 x RMR with an additional 0.6 x RMR as carbohydrate
Number of subjects: 6
Study 8862477 — intervention group
Group type: EXPERIMENTAL
Intervention: High Fat (HF) diet at 1.5 x RMR with an additional 0.6 x RMR as fat
Number of subjects: 6
Study 1536666 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (AUR)
Number of subjects: 335
Study 1536666 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 335
Study 1536666 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Auranofin and Methotrexate
Number of subjects: 335
Study 6388524 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate
Number of subjects: 20
Study 6388524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30946860 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg cortisol
Number of subjects: 0
Study 30946860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27296170 — intervention group
Group type: EXPERIMENTAL
Intervention: Tested toothpaste containing potassium nitrate (5.00%) and zinc citrate (0.50%)
Number of subjects: 0
Study 27296170 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what control was used)
Number of subjects: 0
Study 26823271 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 50
Study 26823271 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 50
Study 24641586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 10,000 IU weekly, titrated up to 50,000 IU weekly if necessary
Number of subjects: 352
Study 24641586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol treatment
Number of subjects: 352
Study 22564753 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of fenofibrate per each hemodialysis day for 4 weeks
Number of subjects: 27
Study 22564753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 20412423 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine (30 mg or 60 mg as needed [PRN])
Number of subjects: 0
Study 20412423 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 17671159 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐BLP25 (peptide vaccine)
Number of subjects: 0
Study 17671159 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study 16536310 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education (1, 2, or 3+ sessions)
Number of subjects: 117
Study 16536310 — intervention group
Group type: COMPARATOR
Intervention: No health education (Group 1)
Number of subjects: 117
Study 11983637 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise classes
Number of subjects: 0
Study 11983637 — intervention group
Group type: COMPARATOR
Intervention: Health education talks
Number of subjects: 0
Study 9445297 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (BUD)
Number of subjects: 157
Study 9445297 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched children with asthma, never treated with corticosteroids for more than 14 days)
Number of subjects: 157
Study 9445297 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 157
Study 7841058 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiotape group (received a copy of the tape to play at home)
Number of subjects: 117
Study 7841058 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not receive a copy of the tape)
Number of subjects: 117
Study 7841058 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiotape group (poor-prognosis patients)
Number of subjects: 117
Study 7841058 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-tape controls)
Number of subjects: 117
Study 2133623 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mmol Mg‐aspartate‐HCl/d for 3 months
Number of subjects: 24
Study 2133623 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 24
Study 383254 — intervention group
Group type: EXPERIMENTAL
Intervention: CVMF (cyclophosphamide, vinblastine, methotrexate, and 5‐fluorouracil)
Number of subjects: 108
Study 383254 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMF (cyclophosphamide, adriamycin, methotrexate, and 5‐fluorouracil)
Number of subjects: 108
Study 31748250 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic resonance‐guided focused ultrasound (tcMRgFUS) thalamotomy
Number of subjects: 0
Study 27806010 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental warm-up (8 × 50 m at 98-102% of critical velocity)
Number of subjects: 13
Study 27806010 — intervention group
Group type: COMPARATOR
Intervention: Control warm-up (4 × 25 m race-pace set)
Number of subjects: 13
Study 25851460 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study 25851460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24028942 — intervention group
Group type: EXPERIMENTAL
Intervention: MMM intervention
Number of subjects: 0
Study 24028942 — intervention group
Group type: COMPARATOR
Intervention: Active‐placebo comparison intervention
Number of subjects: 0
Study 22319896 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing (DB) exercise for 2 minutes
Number of subjects: 12
Study 22319896 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing (DB) exercise for 5 minutes
Number of subjects: 12
Study 22319896 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing (DB) exercise for 10 minutes
Number of subjects: 12
Study 22319896 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing (DB) exercise for 2, 5, and 10 minutes
Number of subjects: 12
Study 19195651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal splint
Number of subjects: 72
Study 19195651 — intervention group
Group type: COMPARATOR
Intervention: Complete cast
Number of subjects: 72
Study 17080543 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 75
Study 17080543 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 75
Study 17080543 — intervention group
Group type: EXPERIMENTAL
Intervention: Both acupuncture and physical therapy
Number of subjects: 75
Study 17080543 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 75
Study 15175836 — intervention group
Group type: EXPERIMENTAL
Intervention: 86Y-DOTA-Phe1-Tyr3-octreotide (13.32 GBq, three cycles of 4.44 GBq each)
Number of subjects: 2
Study 15175836 — intervention group
Group type: COMPARATOR
Intervention: 111In-pentetreotide
Number of subjects: 2
Study 15175836 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 86Y-DOTA-Phe1-Tyr3-octreotide and 111In-pentetreotide
Number of subjects: 2
Study 11557462 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir DF 75 mg
Number of subjects: 0
Study 11557462 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir DF 150 mg
Number of subjects: 0
Study 11557462 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir DF 300 mg
Number of subjects: 0
Study 11557462 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir DF 600 mg
Number of subjects: 0
Study 11557462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9783499 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese subjects
Number of subjects: 317
Study 9783499 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 317
Study 9783499 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 317
Study 7841749 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygiitotorum (T II)
Number of subjects: 30
Study 7841749 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immunosuppressive agents)
Number of subjects: 30
Study 3074295 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet with standard antihypertensive therapy
Number of subjects: 12
Study 3074295 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril administration (25‐50 mg/day) for 4 weeks
Number of subjects: 12
Study 31704275 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial infrared brain stimulation (TIBS), a form of photobiomodulation (PBM), details on dosage and duration not available.
Number of subjects: 0
Study 31704275 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group), details not specified.
Number of subjects: 0
Study 31315657 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture (Ecologic® Barrier; 2.5 × 10^9 colony forming units/g; 2 g; daily)
Number of subjects: 40
Study 31315657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29191799 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention website addressing barriers to organ donation through videos; no specific dosage or duration mentioned.
Number of subjects: 1415
Study 29191799 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention website; no specific dosage or duration mentioned.
Number of subjects: 1415
Study 24633624 — intervention group
Group type: COMPARATOR
Intervention: BCAA-enriched nutrient mixture (BCAA-EN) in Study 1
Number of subjects: 92
Study 24633624 — intervention group
Group type: COMPARATOR
Intervention: BCAA-enriched nutrient mixture (BCAA-EN) in Study 2
Number of subjects: 92
Study 24633624 — intervention group
Group type: COMPARATOR
Intervention: BCAA group in Study 2
Number of subjects: 92
Study 23121600 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-oriented action sequences
Number of subjects: 40
Study 23121600 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred imitation assessment
Number of subjects: 40
Study 21368061 — intervention group
Group type: EXPERIMENTAL
Intervention: Executing waving movements
Number of subjects: 0
Study 21368061 — intervention group
Group type: COMPARATOR
Intervention: No concurrent motor execution (baseline)
Number of subjects: 0
Study 19501786 — intervention group
Group type: EXPERIMENTAL
Intervention: High confederate's food intake
Number of subjects: 100
Study 19501786 — intervention group
Group type: COMPARATOR
Intervention: Low confederate's food intake
Number of subjects: 100
Study 19501786 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsociable confederate's sociability
Number of subjects: 100
Study 19501786 — intervention group
Group type: COMPARATOR
Intervention: Sociable confederate's sociability
Number of subjects: 100
Study 16810002 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.05 mg . kg(‐1) . h(‐1), approximately 3 mg/h)
Number of subjects: 49
Study 16810002 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 49
Study 15502035 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of hyperbaric bupivacaine 0.5% (n = 20)
Number of subjects: 60
Study 15502035 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of hyperbaric levobupivacaine 0.5% (n = 20)
Number of subjects: 60
Study 15502035 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg of hyperbaric ropivacaine 0.5% (n = 20)
Number of subjects: 60
Study 11676331 — intervention group
Group type: COMPARATOR
Intervention: Triple-drug regimen (lansoprazole, clarithromycin, secnidazole)
Number of subjects: 64
Study 11676331 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple-drug regimen (lansoprazole, amoxycillin, colloidal bismuth subcitrate, secnidazole)
Number of subjects: 64
Study 9634207 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV encephalitis observed in all centres
Number of subjects: 1144
Study 9634207 — intervention group
Group type: EXPERIMENTAL
Intervention: Categories of exposure
Number of subjects: 1144
Study 9634207 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxoplasmosis, PML, and cryptococcal infection
Number of subjects: 1144
Study 9634207 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-retroviral treatment (Zidovudine)
Number of subjects: 1144
Study 8202031 — intervention group
Group type: EXPERIMENTAL
Intervention: etoposide (VP-16)
Number of subjects: 0
Study 8202031 — intervention group
Group type: COMPARATOR
Intervention: vinblastine
Number of subjects: 0
Study 3664912 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 20
Study 3664912 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 20
Study 29852853 — intervention group
Group type: EXPERIMENTAL
Intervention: Staircase alveolar recruitment manoeuvres with individually titrated PEEP (maximum 40 cmH2O) and peak pressures (maximum 55 cmH2O).
Number of subjects: 340
Study 29852853 — intervention group
Group type: EXPERIMENTAL
Intervention: Staircase alveolar recruitment manoeuvres with individually titrated PEEP and permissive hypercapnia.
Number of subjects: 340
Study 29852853 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation following the ARDSNet-ARMA trial protocol.
Number of subjects: 340
Study 27401591 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive commercial e-cigarette use
Number of subjects: 105
Study 27401591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-use of commercial e-cigarettes and usual cigarette brand
Number of subjects: 105
Study 27401591 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued use of all tobacco or nicotine products
Number of subjects: 105
Study 27401591 — intervention group
Group type: COMPARATOR
Intervention: Dual users
Number of subjects: 105
Study 24625034 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal phalanx hemiarthroplasty (AnaToemic, Arthrex Ltd., Sheffield, UK)
Number of subjects: 30
Study 24625034 — intervention group
Group type: COMPARATOR
Intervention: Arthrodesis
Number of subjects: 30
Study 24625034 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 30
Study 23529285 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0
Study 23529285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20961382 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07% cetylpyridinium chloride (CPC) mouthrinse
Number of subjects: 30
Study 20961382 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% Hexetidine product (positive control)
Number of subjects: 30
Study 20961382 — intervention group
Group type: COMPARATOR
Intervention: Control product
Number of subjects: 30
Study 19042322 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviorally-based treatment for AOSUD
Number of subjects: 50
Study 12036665 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening dosing of latanoprost 0.005%/timolol maleate 0.5%
Number of subjects: 36
Study 12036665 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing of latanoprost 0.005%/timolol maleate 0.5%
Number of subjects: 36
Study 12036665 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate given twice daily
Number of subjects: 36
Study 12036665 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening dosing of latanoprost/timolol
Number of subjects: 36
Study 9848556 — intervention group
Group type: EXPERIMENTAL
Intervention: Kessler suture
Number of subjects: 40
Study 9848556 — intervention group
Group type: EXPERIMENTAL
Intervention: Strickland suture
Number of subjects: 40
Study 9848556 — intervention group
Group type: EXPERIMENTAL
Intervention: Robertson suture
Number of subjects: 40
Study 9848556 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Becker suture
Number of subjects: 40
Study 9848556 — intervention group
Group type: COMPARATOR
Intervention: Volar placement
Number of subjects: 40
Study 9848556 — intervention group
Group type: COMPARATOR
Intervention: Dorsal placement
Number of subjects: 40
Study 7972188 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient accommodation for oncology patients receiving radiotherapy treatment
Number of subjects: 0
Study 7972188 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic approach to evaluate and cater for the effects of cancer on individuals
Number of subjects: 0
Study 2689909 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose morphinic administered for induction and maintenance of anesthesia without further analgesic and/or narcotic supplement.
Number of subjects: 18
Study 769772 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa (up to 1250 mg daily)
Number of subjects: 28
Study 769772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 30835911 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human soluble thrombomodulin (rhTM) at a dosage of 380 U/kg/day for 6 days
Number of subjects: 100
Study 30835911 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control arm)
Number of subjects: 100
Study 30835911 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human soluble thrombomodulin (rhTM)
Number of subjects: 100
Study 28817370 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m2 days 1, 8, 15, every 4 weeks plus erlotinib 100 mg once per day (GemErlo)
Number of subjects: 436
Study 28817370 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (Gem)
Number of subjects: 436
Study 28817370 — intervention group
Group type: EXPERIMENTAL
Intervention: GemErlo
Number of subjects: 436
Study 28817370 — intervention group
Group type: COMPARATOR
Intervention: Gem
Number of subjects: 436
Study 25362513 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum (Group-C)
Number of subjects: 67
Study 25362513 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group-NC)
Number of subjects: 67
Study 24041815 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii 50 mg/kg every 12 h
Number of subjects: 104
Study 24041815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 21788997 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarsasapogenin plus risperidone
Number of subjects: 80
Study 21788997 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus risperidone
Number of subjects: 80
Study 19328264 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat eating plan delivered by registered dietitians with behavioral, cognitive, and motivational counseling techniques.
Number of subjects: 0
Study 19328264 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat eating plan intervention group.
Number of subjects: 0
Study 19328264 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 16753687 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 IOVE capsule per day (Group 1; n = 562)
Number of subjects: 1080
Study 16753687 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 IOVE capsules per day (Group 2; n = 518)
Number of subjects: 1080
Study 15484298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymatrine capsule (group A)
Number of subjects: 144
Study 15484298 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 144
Study 11777288 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg orally daily)
Number of subjects: 92
Study 11777288 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (50 mg intravenously four times daily)
Number of subjects: 92
Study 9253573 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 600 IU kg‐1
Number of subjects: 80
Study 9253573 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 300 IU kg‐1
Number of subjects: 80
Study 9253573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9253573 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 8512837 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile transparent dressing (Venigard, Consolidated Medical Equipment, London)
Number of subjects: 0
Study 8512837 — intervention group
Group type: COMPARATOR
Intervention: Non‐sterile tape (Mefix, Molnlycke, Sweden)
Number of subjects: 0